Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert PanelArrigo F.G. Cicero, Maciej Banach, Demosthenes B. Panagiotakos et al.|Archives of Medical Science|2017Cited by 288
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert PanelArrigo F.G. Cicero, Maciej Banach, Alessandro Colletti et al.|Nutrition Reviews|2017Cited by 286
The Role of Nutraceuticals in Statin Intolerant PatientsMaciej Banach, Manfredi Rizzo, Angelo Maria Patti et al.|Journal of the American College of Cardiology|2018Cited by 271
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Alberico L. Catapano, Carlos Aguíar et al.|European Heart Journal Supplements|2016Cited by 101
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapyCarlos Aguíar, Roberto Ferrari, Eduardo Alegría et al.|Atherosclerosis Supplements|2015Cited by 84